+

SK7799A3 - Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses - Google Patents

Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses Download PDF

Info

Publication number
SK7799A3
SK7799A3 SK77-99A SK7799A SK7799A3 SK 7799 A3 SK7799 A3 SK 7799A3 SK 7799 A SK7799 A SK 7799A SK 7799 A3 SK7799 A3 SK 7799A3
Authority
SK
Slovakia
Prior art keywords
ige
hsa
polypeptide
leu
glu
Prior art date
Application number
SK77-99A
Other languages
English (en)
Slovak (sk)
Inventor
Mary E Digan
Philip Lake
Hermann Gram
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK7799A3 publication Critical patent/SK7799A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70535Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SK77-99A 1996-07-26 1997-07-25 Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses SK7799A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69021696A 1996-07-26 1996-07-26
PCT/EP1997/004066 WO1998004718A1 (fr) 1996-07-26 1997-07-25 Polypeptides de fusion comprenant un domaine de liaison ige et un composant hsa, et leurs utilisations diagnostiques et therapeutiques

Publications (1)

Publication Number Publication Date
SK7799A3 true SK7799A3 (en) 1999-07-12

Family

ID=24771594

Family Applications (1)

Application Number Title Priority Date Filing Date
SK77-99A SK7799A3 (en) 1996-07-26 1997-07-25 Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses

Country Status (28)

Country Link
EP (1) EP0917581B1 (fr)
JP (1) JP3681402B2 (fr)
KR (1) KR100502879B1 (fr)
CN (1) CN1146664C (fr)
AR (1) AR008077A1 (fr)
AT (1) ATE383429T1 (fr)
AU (1) AU722069B2 (fr)
BR (1) BR9710605A (fr)
CA (1) CA2261562C (fr)
CO (1) CO4650184A1 (fr)
CZ (1) CZ297634B6 (fr)
DE (1) DE69738452T2 (fr)
ES (1) ES2300114T3 (fr)
HK (1) HK1020352A1 (fr)
ID (1) ID19420A (fr)
IL (2) IL128094A0 (fr)
MY (1) MY120425A (fr)
NO (1) NO323611B1 (fr)
NZ (1) NZ333908A (fr)
PE (1) PE99498A1 (fr)
PL (1) PL189415B1 (fr)
PT (1) PT917581E (fr)
RU (1) RU2209211C2 (fr)
SK (1) SK7799A3 (fr)
TR (1) TR199900155T2 (fr)
TW (1) TW565571B (fr)
WO (1) WO1998004718A1 (fr)
ZA (1) ZA976666B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP1056471A4 (fr) * 1998-01-29 2001-05-30 Tanox Inc TRAITEMENT DE LA DERMATITE ATOPIQUE A L'AIDE D'ANTAGONISTES D'IgE
DE69933216T2 (de) * 1998-06-15 2007-09-20 GTC Biotherapeutics, Inc., Framingham Erythropoietin-analog-menschliches serum-albumin fusionsprotein
EP1208194A2 (fr) * 1999-08-09 2002-05-29 Genaissance Pharmaceuticals, Inc. Isogenes cibles de medicaments : polymorphismes dans le gene de la sous-unite alpha du recepteur i de l'immunoglobuline e
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003530846A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
DE10026998A1 (de) * 2000-05-31 2001-12-13 Fresenius Kabi De Gmbh Verfahren zur Herstellung einer kosmetischen Zusammensetzung, die humanes Serum Albumin umfasst, welches aus transgenen nicht-menschlichen Säugern erhalten wurde
DE60135581D1 (de) * 2000-12-07 2008-10-09 Lilly Co Eli Glp-1 fusion proteine
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (fr) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Proteines hybrides d'albumine
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
SG173457A1 (en) 2009-02-27 2011-09-29 Novartis Ag Methods for selecting eukaryotic cells expressing a heterologous protein
WO2012169735A2 (fr) * 2011-06-07 2012-12-13 (주)네오팜 Complexe comprenant des fragments hydrosolubles de fcεri et composition le contenant pour traiter les maladies allergiques médiées par l'ige
RU2506271C2 (ru) * 2011-06-22 2014-02-10 Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД А2, СЕЛЕКТИВНО СВЯЗЫВАЮЩИЙ HSA, РЕКОМБИНАНТНАЯ ДНК pa2, КОДИРУЮЩАЯ HSA-СВЯЗЫВАЮЩУЮ ЧАСТЬ ПОЛИПЕПТИДА A2, ЕГО ПРОДУЦЕНТ - РЕКОМБИНАНТНЫЙ ШТАММ Escherichia coli M15-A2, СОДЕРЖАЩИЙ РЕКОМБИНАНТНУЮ ПЛАЗМИДНУЮ ДНК pQE 32-pa2, ОБЕСПЕЧИВАЮЩУЮ ПОЛУЧЕНИЕ ПОЛИПЕПТИДА A2 И ПРИМЕНЕНИЕ ПОЛИПЕПТИДА А2 ДЛЯ ДИАГНОСТИКИ МИКРОАЛЬБУМИНУРИИ И ВЫДЕЛЕНИЯ HSA ИЗ СЫВОРОТКИ КРОВИ
WO2014036520A1 (fr) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Polythérapies comprenant des agents anti-erbb3
US20180139938A1 (en) * 2015-05-04 2018-05-24 Laboratoire Français du Fractionnement et des, Biotechnologies Transgenic production of fc fusion proteins
EP3192806A1 (fr) 2016-01-13 2017-07-19 Affiris AG Chaîne alpha du récepteur de l'ige haute affinité (fceria)
EP3538558A4 (fr) 2016-11-09 2020-07-15 North Carolina State University Traitement de maladies allergiques au moyen d'une protéine chimérique
WO2019183437A1 (fr) 2018-03-23 2019-09-26 North Carolina State University Procédés et compositions pour un anticorps dirigé contre un récepteur ige de haute affinité
JP7497417B2 (ja) * 2019-07-08 2024-06-10 プロジェン・カンパニー・リミテッド 新規il-10変異体タンパク質及びその用途
CA3145382A1 (fr) 2019-07-08 2021-01-14 Gi Innovation, Inc. Dimere polypeptidique a haute teneur en acide sialique, comprenant un domaine extracellulaire de sous-unite alpha du recepteur fc d'ige, et composition pharmaceutique le comprenant
CN111773392B (zh) * 2020-05-25 2023-04-07 河南省生物工程技术研究中心 一种人血白蛋白/寡核苷酸纳米颗粒及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962035A (en) * 1987-12-01 1990-10-09 President And Fellows Of Harvard College DNA encoding IgE receptor alpha-subunit or fragment thereof
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
CA2059842A1 (fr) * 1991-02-11 1992-08-12 Richard A. Chizzonite Anticorps recepteurs d'ige

Also Published As

Publication number Publication date
ID19420A (id) 1998-07-09
WO1998004718A1 (fr) 1998-02-05
NO990328D0 (no) 1999-01-25
EP0917581A1 (fr) 1999-05-26
RU2209211C2 (ru) 2003-07-27
CA2261562A1 (fr) 1998-02-05
CN1146664C (zh) 2004-04-21
JP2000516089A (ja) 2000-12-05
DE69738452D1 (de) 2008-02-21
DE69738452T2 (de) 2008-12-24
ES2300114T3 (es) 2008-06-01
ZA976666B (en) 1999-01-25
EP0917581B1 (fr) 2008-01-09
CA2261562C (fr) 2011-04-05
AU4202597A (en) 1998-02-20
TR199900155T2 (xx) 2000-08-21
AU722069B2 (en) 2000-07-20
NZ333908A (en) 1999-10-28
MY120425A (en) 2005-10-31
CN1229439A (zh) 1999-09-22
JP3681402B2 (ja) 2005-08-10
PL189415B1 (pl) 2005-08-31
IL128094A (en) 2006-08-20
KR20000029563A (ko) 2000-05-25
CO4650184A1 (es) 1998-09-03
KR100502879B1 (ko) 2005-07-25
BR9710605A (pt) 1999-08-17
NO323611B1 (no) 2007-06-18
PT917581E (pt) 2008-04-11
PL331356A1 (en) 1999-07-05
CZ297634B6 (cs) 2007-02-21
HK1020352A1 (en) 2000-04-14
AR008077A1 (es) 1999-12-09
TW565571B (en) 2003-12-11
CZ24699A3 (cs) 1999-04-14
ATE383429T1 (de) 2008-01-15
NO990328L (no) 1999-02-19
PE99498A1 (es) 1999-01-21
IL128094A0 (en) 1999-11-30

Similar Documents

Publication Publication Date Title
SK7799A3 (en) Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses
EP3248610B1 (fr) Mutants de fgf21 et leurs utilisations
CN103328502B (zh) 治疗fgf21相关的病症的方法
EP2296690B1 (fr) Mutants fgf21 et leurs utilisations
US7576190B2 (en) FGF-21 fusion proteins
US20120052069A1 (en) Fgf21 mutants and uses thereof
US20050175610A1 (en) Modified chimeric polypeptides with improved pharmacokinetic properties and methods of making and using thereof
US6423512B1 (en) Fusion polypeptides
MXPA99000970A (en) Fusion polypeptides com0prising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses
AU2014202582A1 (en) FGF21 mutants and uses thereof
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载